Companies such as Gilead Sciences and Eli Lilly working together to develop combined Covid-19 treatments will find it “difficult” to co-market drugs, says an analyst.

The two firms, which are investigating a combination of remdesivir and baricitinib (Olumiant) to treat severely ill coronavirus patients, may face challenges further down the line — especially because these medicines cannot be integrated into a single regimen.

Read the full article here.